Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 14/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | APLNR | P35414 | 2/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30795719 | 1.00 | GRM5 (0.67) | GRM5KCNH2APLNRPSEN1PSEN2 | |
| SCHEMBL2891488 | 0.90 | GRM5 (0.69) | GRM5KCNH2 | |
| SCHEMBL1997217 | 0.87 | GRM5 (0.65) | GRM5KCNH2RXRAGRIN1GRIN2B | |
| SCHEMBL30795975 | 0.87 | GRM5 (0.65) | GRM5KCNH2RXRAGRIN1GRIN2B | |
| SCHEMBL12612195 | 0.85 | GRM5 (0.69) | GRM5KCNH2 | |
| SCHEMBL2491421 | 0.85 | GRM5 (0.69) | GRM5KCNH2 | |
| SCHEMBL2005352 | 0.85 | GRM5 (0.71) | GRM5KCNH2APLNRRXRAGRIN1 | |
| SCHEMBL30795977 | 0.85 | GRM5 (0.71) | GRM5KCNH2APLNRRXRAGRIN1 | |
| SCHEMBL2006383 | 0.83 | GRM5 (0.64) | GRM5KCNH2RXRAGRIN1GRIN2B | |
| SCHEMBL30794700 | 0.83 | GRM5 (0.64) | GRM5KCNH2RXRAGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131454-A1 | New compounds 067 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | claimed |
| US-7960422-B2 | Pharmaceutically active compounds containing tetrazolyl and triazolyl rings | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-7960422-B2 | Pharmaceutically active compounds containing tetrazolyl and triazolyl rings | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-7960422-B2 | Pharmaceutically active compounds containing tetrazolyl and triazolyl rings | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-20090131454-A1 | New compounds 067 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131454-A1 | New compounds 067 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131454-A1 | New compounds 067 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| WO-2009051556-A1 | TETRAZOLE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS (MGLURS) | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131454-A1 | New compounds 067 | UGT2B7, UGT1A7, CYP3A7 | GRM5 1146/4885KCNH2 4421/4885APLNR 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.